Fibrinolytic treatment for elderly patients with acute myocardial infarction

Heart

Volumn 87, Issue 4, 2002, Pages 308-311

  Estess, J M ^a   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; STREPTOKINASE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; AGED; BLEEDING; BOLUS INJECTION; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ELDERLY CARE; FIBRINOLYSIS; HEART INFARCTION SIZE; HUMAN; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STROKE; TREATMENT PLANNING;

EID: 0036214757     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.87.4.308     Document Type: Review

References (31)

1. Thrombolytic therapy for elderly patients
2. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years
3. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
4. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction
5. A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction
6. A randomized trial of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction
7. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
8. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction
9. A comparison of reteplase with alteplase for acute myocardial infarction
10. Randomized trial of late thrombolysis in patients with suspected acute myocardial infarction
11. Late Assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction
12. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity result from all randomized trials of more than 1000 patients
13. Age and outcome with contemporary thrombolytic therapy (results from the GUSTO-I trial)
14. Thrombolysis is beneficial in elderly acute myocardial infarction patients
15. Thrombolytic therapy in older patients
16. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41021 patients
17. Pre-hospital thrombolytic therapy in patients with suspected acute myocardial infarction
18. Early treatment with thrombolytic therapy: Results from the myocardial infarction, triage and intervention pre-hospital trial
19. Prognostic significance of the extent of myocardial injury in acute myocardial infarction treated by streptokinase (the GISSI trial)
20. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment
21. A comparison of the early outcome of acute myocardial infarction in women and men
22. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy
23. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction
24. Death or nonfatal stroke in patients with acute myocardial infarction treated with tissue plasminogen activator
25. Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction
26. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction
27. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on management of acute myocardial infarction)
28. Individual risk assessment for intracranial hemorrhage during thrombolytic therapy
29. Selection of thrombolytic therapy for individual patients: Development of a clinical model
30. Comparison of intracranial hemorrhage rates in patients treated with rt-PA and TNK-tPA: Impact of gender, age and low body weight
31. Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction. Results from the cooperative cardiovascular project